SECURITIES
      ESCROW AGREEMENT

     

    THIS
      SECURITIES ESCROW AGREEMENT, dated as of                 ,
      2007
      (the “Agreement”),
      by
      and among APEX BIOVENTURES ACQUISITION CORPORATION, a Delaware corporation
      (the
“Company”),
      the
      undersigned parties listed under Initial Stockholders on the signature page
      hereto (collectively, the “Initial
      Stockholders”)
      and
      CONTINENTAL STOCK TRANSFER & TRUST COMPANY, a New York corporation (the
“Escrow
      Agent”).

     

    WHEREAS,
      the Company has entered into an Underwriting Agreement, dated
      _________,
      2007
      (“Underwriting
      Agreement”),
      with Lazard Capital Markets LLC and Ladenburg Thalmann & Co. Inc. (the
      "Underwriters"), each acting
      as
      underwriter, pursuant to which, among other matters, the Underwriters
      have agreed to purchase 7,500,000 units (the “Units”)
      of the
      Company’s securities.  Each Unit consists of one share of the Company’s
      common stock, par value $0.0001 per share (“Common
      Stock”),
      and
      one Warrant, each Warrant to purchase one share of Common Stock, all as more
      fully described in the Company’s final Prospectus, dated                ,
      2007
      (the “Prospectus”),
      comprising part of the Company’s Registration Statement on Form S-1, as amended
      (File No. 333-135755) under the Securities Act of 1933, as amended
      (the “Registration
      Statement”),
      which
      was declared effective on                     ,
      2007
      (the “Effective
      Date”); 

     

    WHEREAS,
      the Initial Stockholders have agreed as a condition of the sale of the Units
      to
      deposit (a) those shares of Common Stock of the Company purchased by each of
      them as set forth opposite their respective names under the heading “Number of
      Founder Shares” in Exhibit
      A
      attached
      hereto (collectively, the “Founder
      Shares”),
      and
      (b) including those shares of Common Stock of the Company set forth
      opposite their respective names under the heading “Forfeitable Shares” in
Exhibit
      A
      attached
      hereto (collectively the “Forfeitable
      Shares” and collectively,
      with the Founder Shares, plus such additional shares as may be hereafter
      deposited into escrow pursuant to Section 4.2 or otherwise, less such
      Forfeitable Shares which may be forfeited in accordance with the
      Share Forfeiture Agreement (defined below) and Section 3 below, the
“Escrow
      Shares”),
      in
      escrow as hereinafter provided; 


    
       

      WHEREAS,
        the Company has entered into a Warrant Purchase Agreement with the Initial
        Stockholders (the “Initial
        Warrantholders”),
        dated
        __________ __, 2007 (the “Warrant
        Purchase Agreement”),
        pursuant to which the Initial Warrantholders have agreed to purchase 1,800,000
        warrants (the “Founding
        Director Warrants”)
        in a
        private placement transaction;

       

      WHEREAS,
        the Initial Warrantholders have agreed as a condition of the sale of the
        Founding Director Warrants to deposit the Founding Director Warrants (together
        with the Escrow Shares, the “Escrow
        Securities”),
        with
        the Escrow Agent as hereinafter provided; 

    

     

    WHEREAS,
      the Company and each of the Initial Stockholders have entered into a letter
      agreement, dated as of _______, 2007 (the “Share
      Forfeiture Agreement”),
      pursuant to which each of the Initial Stockholders have agreed to the
      forfeiture of some or all of their Forfeitable Shares under certain
      circumstances; and

    


    WHEREAS,
      the Company and the Initial Stockholders (such term as used herein includes
      the
      Initial Warrantholders) desire that the Escrow Agent accept the Escrow
      Securities, in escrow, to be held and disbursed as hereinafter
      provided.

    


    NOW,
      THEREFORE, in consideration of the premises and the mutual covenants,
      representations and warranties contained herein and intending to be legally
      bound hereby, the parties hereto agree as follows:

     

    1. Appointment
      of Escrow Agent. 
      The Company and the Initial Stockholders hereby appoint the Escrow Agent to
      act
      in accordance with and subject to the terms of this Agreement, and the Escrow
      Agent hereby accepts such appointment and agrees to act in accordance with
      and
      subject to such terms.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    2. Deposit
      of Escrow Securities. 
      On or before the Effective Date, each of the Initial Stockholders shall deliver
      to the Escrow Agent certificates representing his or her respective Escrow
      Securities, to be held and disbursed subject to the terms and conditions of
      this
      Agreement.  Each Initial Stockholder acknowledges that the certificate
      representing his or her Escrow Securities is legended to reflect the deposit
      of
      such Escrow Securities under this Agreement.

     

    3. Disbursement
      of the Escrow Securities. 
      (a) The Escrow Agent shall hold the Escrow Shares until (a) the expiration
      of
      one year from consummation of the Company’s initial Business Combination (as
      such term is defined in the Certificate of Incorporation of the Company), or
      (b)
      any time after six months from consummation of a Business Combination if the
      volume weighted average price of the Common Stock equals or exceeds $11.50
      per
      share for any 20 trading days within any 30 trading day period (the
“Escrow
      Shares Escrow Period”),
      on
      which date it shall, upon written instructions from each Initial Stockholder,
      disburse each of the Initial Stockholder’s Escrow Shares to such Initial
      Stockholder; provided, however, that (i) upon receipt of joint written notice
      from the Company and the Initial Stockholders that some or all of
      the Forfeitable Shares have been forfeited pursuant to the Share
      Forfeiture Agreement, the Escrow Agent will release to the Company all of
      the stock certificates evidencing Forfeitable Shares (it being understood
      that, if the Company has elected to purchase less than all of the Forfeitable
      Shares, it shall (A) issue new stock certificates, registered to each of the
      Initial Stockholders, representing the Forfeitable Shares held by each Initial
      Stockholder which have not be so purchased, and (B) deliver such new stock
      certificates to the Escrow Agent to hold pursuant to this Agreement), (ii)
      if
      the Escrow Agent is notified by the Company pursuant to Section 6.7 hereof
      that the Company is being liquidated at any time during the Escrow Shares Escrow
      Period, then immediately prior to the effectiveness of such liquidation, the
      Escrow Agent shall promptly destroy the certificates representing the Escrow
      Shares and the Escrow Shares shall no longer be considered to be issued and
      outstanding securities of the Company, and (iii) if, after the Company
      consummates a Business Combination (as such term is defined in the Registration
      Statement), it (or the surviving entity) subsequently consummates a liquidation,
      merger, stock exchange or other similar transaction which results in all of
      the
      stockholders of such entity having the right to exchange their shares of Common
      Stock for cash, securities or other property, then the Escrow Agent will, upon
      receipt of a certificate, executed by the Chairman, Chief Executive Officer
      or Chief Financial Officer of the Company, in form reasonably
      acceptable to the Escrow Agent, that such transaction is then being consummated,
      release the Escrow Shares to the Initial Stockholders upon consummation of
      the
      transaction so that they can similarly participate. The Escrow Agent shall
      have
      no further duties hereunder after the disbursement or destruction of the Escrow
      Shares in accordance with this Section 3(a).

     

    
      (b)
        The
        Escrow Agent shall hold the Founding Director Warrants until such date that
        is
        six (6) months following the date that the Company consummates a Business
        Combination (as such term is defined in the Registration Statement) (the
        “Founding
        Director Warrants Escrow Period”);
        provided, however, that if the Escrow Agent is notified by the Company pursuant
        to Section 6.7 hereof that the Company is being liquidated at any time during
        the Founding Director Warrants Escrow Period, then immediately prior to the
        effectiveness of such liquidation, the Escrow Agent shall promptly destroy
        the
        certificates representing the Founding Director Warrants and the Founding
        Director Warrants shall no longer be considered issued and outstanding
        securities of the Company. The Escrow Agent shall have no further duties
        hereunder after the disbursement or destruction of the Founding Director
        Warrants in accordance with this Section 3(b).

    

     

    4. Rights
      of Initial Stockholders in Escrow Shares.

     

    4.1 Voting
      Rights as a Stockholder. 
      Subject to the terms of the Insider Letters described in Section 4.4
      hereof, and except as herein provided, the Initial Stockholders shall retain
      all
      of their rights as stockholders of the Company during the Escrow Period,
      including, without limitation, the right to vote their Escrow
      Shares.

     

    4.2 Dividends
      and Other Distributions in Respect of the Escrow Shares. 
      During the Escrow Period, all dividends payable in cash with respect to the
      Escrow Shares shall be paid to the Initial Stockholders, but all dividends
      payable in stock or other non-cash property (the “Non-Cash
      Dividends”)
      shall
      be delivered to the Escrow Agent to hold in accordance with the terms
      hereof.  As used herein, the term “Escrow Shares” shall be deemed to
      include the Non-Cash Dividends distributed thereon, if any.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    4.3 Restrictions
      on Transfer. 
      During the Escrow Share Escrow Period or the Founding Director Warrants Escrow
      Period, as applicable, no sale, transfer or other disposition may be made of
      any
      or all of the Escrow Securities except, with respect to (a) an Initial
      Stockholder that is an entity, a dividend, distribution or contribution to
      any
      individual or entity controlling, controlled by, or under common control with
      such Initial Stockholder, or any stockholder, member, partner or limited partner
      of such Initial Stockholder, for which no or nominal consideration is received,
      and (b) with respect to an Initial Stockholder who is an individual, (i) to
      a
      member of Initial Stockholder’s immediate family or to a trust, the beneficiary
      of which is an Initial Stockholder or a person related to an Initial Stockholder
      by blood, marriage or adoption, or (ii) by virtue of the laws of descent and
      distribution upon death of any Initial Stockholder; provided,
      however,
      that
      such permissive transfers may be implemented only upon the respective
      transferee’s written agreement to be bound by the terms and conditions of this
      Agreement and of the Insider Letter signed by the Initial Stockholder
      transferring the Escrow Securities.  During the Escrow Period, no Initial
      Stockholder shall pledge or grant a security interest in his, her or its Escrow
      Securities or grant a security interest in his, her or its rights under this
      Agreement.

     

    4.4 Insider
      Letters. 
      Each of the Initial Stockholders has executed a letter agreement with the
      Underwriters and the Company, dated as indicated on Exhibit A
      hereto,
      and which is filed as an exhibit to the Registration Statement (“Insider
      Letter”),
      respecting the rights and obligations of such Initial Stockholder in certain
      events, including, but not limited to, the liquidation of the
      Company.

     

    5. Concerning
      the Escrow Agent.

     

    5.1 Good
      Faith Reliance. 
      The Escrow Agent shall not be liable for any action taken or omitted by it
      in
      good faith and in the exercise of its own best judgment, and may rely
      conclusively and shall be protected in acting upon any order, notice, demand,
      certificate, opinion or advice of counsel (including counsel chosen by the
      Escrow Agent), statement, instrument, report or other paper or document (not
      only as to its due execution and the validity and effectiveness of its
      provisions, but also as to the truth and acceptability of any information
      therein contained) which is believed by the Escrow Agent to be genuine and
      to be
      signed or presented by the proper person or persons.  The Escrow Agent
      shall not be bound by any notice or demand, or any waiver, modification,
      termination or rescission of this Agreement unless evidenced by a writing
      delivered to the Escrow Agent signed by the proper party or parties and, if
      the
      duties or rights of the Escrow Agent are affected, unless it shall have given
      its prior written consent thereto.

     

    5.2 Indemnification. 
      The Escrow Agent shall be indemnified and held harmless by the Company from
      and
      against any expenses, including counsel fees and disbursements, or loss suffered
      by the Escrow Agent in connection with any action, suit or other proceeding
      involving any claim which in any way, directly or indirectly, arises out of
      or
      relates to this Agreement, the services of the Escrow Agent hereunder, or the
      Escrow Shares held by it hereunder, other than expenses or losses arising from
      the gross negligence or willful misconduct of the Escrow Agent.  Promptly
      after the receipt by the Escrow Agent of notice of any demand or claim or the
      commencement of any action, suit or proceeding, the Escrow Agent shall notify
      the other parties hereto in writing.  In the event of the receipt of such
      notice, the Escrow Agent, in its sole discretion, may commence an action in
      the
      nature of interpleader in an appropriate court to determine ownership or
      disposition of the Escrow Securities or it may deposit the Escrow Securities
      with the clerk of any appropriate court or it may retain the Escrow Securities
      pending receipt of a final, non-appealable order of a court having jurisdiction
      over all of the parties hereto directing to whom and under what circumstances
      the Escrow Securities are to be disbursed and delivered.  The provisions of
      this Section 5.2 shall survive in the event the Escrow Agent resigns or is
      discharged pursuant to Sections 5.5 or 5.6 below.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    5.3 Compensation. 
      The Escrow Agent shall be entitled to reasonable compensation from the Company
      for all services rendered by it hereunder, as set forth on Exhibit B
      hereto.  The Escrow Agent shall also be entitled to reimbursement from the
      Company for all expenses paid or incurred by it in the administration of its
      duties hereunder including, but not limited to, all legal counsel and agents’
fees and disbursements and all taxes or other governmental charges.

     

    5.4 Further
      Assurances. 
      From time to time, on and after the date hereof, the Company and the Initial
      Stockholders shall deliver, or cause to be delivered, to the Escrow Agent such
      further documents and instruments and shall do or cause to be done such further
      acts as the Escrow Agent shall reasonably request to carry out more effectively
      the provisions and purposes of this Agreement, to evidence compliance herewith
      or to assure itself that it is protected in acting hereunder.

     

    5.5 Resignation. 
      The Escrow Agent may resign at any time and be discharged from its duties as
      escrow agent hereunder by its giving the other parties hereto written notice
      and
      such resignation shall become effective as hereinafter provided.  Such
      resignation shall become effective at such time that the Escrow Agent shall
      turn
      over to a successor escrow agent appointed by the Company and approved by Lazard
      Capital Markets LLC, the Escrow Securities held hereunder.  If no new
      escrow agent is so appointed within the sixty (60) day period following the
      giving of such notice of resignation, the Escrow Agent may deposit the Escrow
      Securities with any court it reasonably deems appropriate.

     

    5.6 Discharge
      of Escrow Agent. 
      The Escrow Agent shall resign and be discharged from its duties as escrow agent
      hereunder if so requested in writing at any time by the Company and a majority
      of the Initial Stockholders, jointly; provided, however, that such resignation
      shall become effective only upon acceptance of appointment by a successor escrow
      agent as provided in Section 5.5.

     

    5.7 Liability. 
      Notwithstanding anything herein to the contrary, the Escrow Agent shall not
      be
      relieved from liability hereunder for its own gross negligence or its own
      willful misconduct.

     

    6.  Miscellaneous.

     

    6.1 Governing
      Law. This
      Agreement shall for all purposes be deemed to be made under and shall be
      construed in accordance with the laws of the State of New York. Each of the
      parties hereby agrees that any action, proceeding or claim against it arising
      out of or relating in any way to this Agreement shall be brought and enforced
      in
      the courts of the State of New York or the United States District Court for
      the
      Southern District of New York (each, a “New
      York court”),
      and
      irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive.
      Each of the parties hereby waives any objection to such exclusive jurisdiction
      and that such courts represent an inconvenient forum. 

     

    6.2 Third
      Party Beneficiaries. 
      Each of the Initial Stockholders hereby acknowledges that the Underwriters
      are third party beneficiaries of this Agreement and this Agreement may not
      be modified or changed without the prior written consent of the
      Underwriters.

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    6.3 Entire
      Agreement. 
      This Agreement contains the entire agreement of the parties hereto with respect
      to the subject matter hereof and, except as expressly provided herein, may
      not
      be changed or modified except by an instrument in writing signed by the party
      to
      be charged and by the Underwriters. 

     

    6.4  Headings. 
      The headings contained in this Agreement are for reference purposes only and
      shall not affect in any way the meaning or interpretation thereof.

     

    6.5 Binding
      Effect. 
      This Agreement shall be binding upon and inure to the benefit of the respective
      parties hereto and their legal representatives, successors and
      assigns.

     

    6.6 Notices. 
      Any notice or other communication required or which may be given hereunder
      shall
      be in writing and either be delivered personally or be mailed, certified or
      registered mail, or by private national courier service, return receipt
      requested, postage prepaid, and shall be deemed given when so delivered
      personally or, if mailed, two days after the date of mailing, as
      follows:

     

    If
      to the
      Company, to:

    Apex
      Bioventures Acquisition Corporation

    18
      Farm
      Lane

    Hillsborough,
      California 94010

    Attention:
      Chief Executive Officer

     

    If
      to a
      an Initial Stockholder, to his, her or its address set forth in Exhibit
      A;

    


    and
      if to
      the Escrow Agent, to:

    


    Continental
      Stock Transfer & Trust Company 

    17
      Battery Place

    New
      York,
      New York 10004

    Attention:  Chairman

    


    A
      copy of
      any notice sent hereunder shall be sent (which shall not constitute notice)
      to:

     

    Mintz,
      Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    666
      Third
      Avenue, 25th Floor

    New
      York,
      New York 10017

    Attention: Joel
      I.
      Papernik, Esq. and

    Jeffrey
      P. Schultz, Esq.

    and:

    Lazard
      Capital Markets LLC

    30
      Rockefeller Plaza

    New
      York, NY 10020

    Attention:
      Stephen Sands

     

    Ladenburg
      Thalmann & Co. Inc.

    153
      East 53rd Street, 49th Floor

    New
      York, NY 10022

    Attention:
      Peter H. Blum

     

    Kramer
      Levin Naftalis & Frankel LLP

    1177
      Avenue of the Americas

    New
      York, NY 10036

    Attention:
      Christopher S. Auguste, Esq.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    The
      parties may change the persons and addresses to which the notices or other
      communications are to be sent by giving written notice to any such change in
      the
      manner provided herein for giving notice.

     

    6.7 Liquidation
      of Company.
      The
      Company shall give the Escrow Agent written notification of the liquidation
      and
      dissolution of the Company in the event that the Company fails to consummate
      a
      Business Combination within the time period(s) specified in the
      Prospectus.

    

      6.8 Waiver.
        Notwithstanding anything herein to the contrary, the Escrow Agent hereby
        waives
        any and all right, title, interest or claim of any kind (“Claim”) in
        or to any distribution of the Trust Account, and hereby agrees not to seek
        recourse, reimbursement, payment or satisfaction for any Claim against the
        Trust
        Account for any reason whatsoever.

    

     

    6.9 Counterparts.
      This
      Agreement may be executed in several counterparts, each one of which may be
      delivered by facsimile transmission and each of which shall constitute an
      original, and together shall constitute but one instrument.

     

    (Remainder
      of page intentionally left blank. Signature pages to follow.)

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the undersigned have executed this Stock Escrow Agreement
      as of
      the date first written above. 

     

    
      	
              COMPANY:

            	 	APEX
              BIOVENTURES
              ACQUISITION CORPORATION 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	
            	 	By: 	
            
	
            	 	 	
              
Darrell
              J. Elliott, Chief Executive Officer
	 	 	 	  
	 	 	 	  


    

    
      
        	
                
                  INITIAL
                    STOCKHOLDERS:

                

              	 	
                
K.
                MICHAEL FORREST 
	
              	 	 	 
	
              	 	
              	 
	
              	 	
                
JOHN
                J. CHANDLER
	 	 	 
	 	 	 
	 	 	
                
                  
NANCY
                  T. CHANG 

              
	 	 	 
	 	 	 
	 	 	
                
ROBERT
                J. EASTON


      

      
        
          	 	 	 	 
	 	 	 	 
	 	 	INVIVOS LIMITED
                  PARTNERS 
	 	 	 	 
	 	 	By: 	Invivos Partners, Ltd., its general
                  partner 
	 	 	 	 
	 	 	By: 	 
	 	 	 	
                  
Darrell
                  J. Elliott, President  
	 	 	 	 
	 	 	 	 
	 	 	TREASURE ROAD PARTNERS,
                  LTD. 
	 	 	 	 
	 	 	By: 	 
	 	 	 	
                  
Gary
                  E. Frashier, Manager 
	 	 	 	 
	 	 	
                  
ANTHONY
                  J. SINSKEY
	 	 	 	 
	 	 	 	 
	 	 	
                  
ROBERT
                  L. VAN
                  NOSTRAND  


        

        
           

           

          
            	 	 	RIX
                    CLINICAL LABORATORIES LTD.   
	 	 	 	 
	 	 	By:	 
	
                  	 	 	
                    
Name:
Title:


          

           

        

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     EXHIBIT
      A

    TO

    SECURITIES
      ESCROW AGREEMENT

     

    
      	
              Name
                and Address of

              Initial
                Stockholder 

            	
               

            	 

              Number

              of
                Founder Shares

            	
               

            	 

              Stock

              Certificate
                Number

            	
               

            	 

              Number

              of Forfeitable
                Shares

            	
               

            	 

              Stock

              Certificate
                Number

            	
               

            	
              Number
                of
Warrants

            	
               

            	
              Warrant
                No.

            	 	 

              Date
                of

              Insider
                Letter

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              John
                J. Chandler

              610
                West Brown Street

              Southport,
                NC 28461

            	 	
               

              109,837

            	 	
               

               

            	 	
               

              16,476

            	 	 

               

            	 	
               75,000

            	 	 	 	
               

              
                _____ __,
                  2007

              

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Nancy
                T. Chang

              10301
                Stella Link

              Houston,
                TX 77025

            	 	
               

              159,957

            	 	
               

               

            	 	
               

              23,994

            	 	 

               

            	 	
              200,000

            	 	 	 	
               

              
                _____
                  __, 2007

              

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Robert
                J. Easton

              c/o
                Craig Drill Capital

              724
                Fifth Avenue

              New
                York, NY 10019

            	 	
               

              345,487

            	 	
               

               

            	 	
               

              51,823

            	 	 

               

            	 	
              325,000

            	 	 	 	
               

              
                _____
                  __, 2007

              

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              K.
                Michael Forrest

              18
                Farm Lane

              Hillsborough,
                CA 94010

            	 	 

              411,133

            	 	 

               

            	 	 

              61,670

            	 	 

               

            	 	
              335,000

            	 	 	 	 

              _____
                __, 2007

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Invivos
                Limited Partners

              1763
                Orkney Place

              North
                Vancouver, BC V7H 2Z1

            	 	
               

              233,790

            	 	
               

               

            	 	
               

              35,068

            	 	 

               

            	 	
              225,000

            	 	 	 	
               

              
                _____
                  __, 2007

              

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Treasure
                Road Partners, Ltd.

              215
                West Bandera Road, Suite 114

              Boerne,
                TX 78006

            	 	
               

              312,861

            	 	
               

               

            	 	
               

              46,929

            	 	 

               

            	 	
              325,000

            	 	 	 	
               

              
                _____
                  __, 2007

              

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Anthony
                J. Sinskey

              Department
                of Biology, Room 68-30A

              Massachusetts
                Institute of Technology

              Cambridge,
                MA 02139

            	 	
               

              84,760

            	 	
               

               

            	 	
               

              12,714

            	 	 

               

            	 	
              100,000

            	 	 	 	
               

              
                _____
                  __, 2007

              

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Robert
                L. Van Nostrand

              Mariners
                Circle

              West
                Islip, NY 11795

            	 	
               

              132,415

            	 	
               

               

            	 	
               

              19,862

            	 	 

               

            	 	
              115,000

            	 	 	 	
               

              
                _____
                  __, 2007

              

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Rix
                Clinical Laboratories Ltd. 
#101-4606
                Canada Way

              Burnaby, BC V5G 1K5

            	 	
               

              84,760

            	 	 	 	
               

              12,714

            	 	 	 	
              100,000

            	 	 	 	 

              _____
                __, 2007

            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total 	 	
              1,875,000

            	 	 	 	
               281,250

            	 	 	 	
               1,800,000

            	 	 	 	 


    

     

     

    
      
        
        

      

      
        
          A-1